Drugs / Measles, mumps, and rubella vaccine; Priorix
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT00488683 Background | Jul 2007 → May 2009 | meningococcal infection | Novartis Vaccines | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Measles, mumps, and rubella vaccine; Priorix | “Measles, mumps, and rubella vaccine; Priorix” NCT00488683 ↗ |
| Known as | MMR | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00488683 ↗ |
| Modality | Vaccine | “routine vaccines - 3 doses of DTaP-Hib-IPV (at 2, 3, and 4 months), 3 doses of PCV (at 2, 4, and 13 months), and 1 dose each of MMR and Hib (booster) at 13 months.” NCT00488683 ↗ |
| Route | Intramuscular | “IM injection of one dose of 0.5 mL of MMR obtained by extemporaneous mixing” NCT00488683 ↗ |